Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes

Current Medical Research and Opinion

Volumn 21, Issue 7, 2005, Pages 989-998

  Home, Philip ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Blood glucose; Diabetes complications; Diabetes mellitus; Glucose tolerance test; Hyperglycaemia; Nateglinide; Post prandial glucose control

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; BIPHASIC INSULIN; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN LISPRO; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; MIGLITOL; NATEGLINIDE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA; TROGLITAZONE; VOGLIBOSE;

ATHEROGENESIS; CARDIOVASCULAR RISK; CELL DAMAGE; DRUG MECHANISM; ENDOTHELIUM CELL; FEEDING BEHAVIOR; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; POSTPRANDIAL STATE; PREVALENCE; PROTEIN BLOOD LEVEL; REVIEW; VASCULAR DISEASE;

ARTERIOSCLEROSIS; BLOOD GLUCOSE; CAPILLARIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; POSTPRANDIAL PERIOD; RISK FACTORS;

EID: 22744439545     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X49662     Document Type: Review

References (83)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44
2. Geiss LS, Herman WH, Smith PJ. Mortality in non-insulin-dependent diabetes. In: Harris MI, Cowie CC, Stern MP, Bokyo EJ, Reiber GE, Bennet PH, editors. Diabetes in America, 2nd ed. Washington (DC); US Government Printing Office; 1995. p. 233-57
3. Kuusisto J, Mykkanen L, Pyorälä K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994;43:960-7
4. Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J. Diabetes, asymptomatic hyperglycaemia, and 2 2-year mortality in black and white men [The Chicago Heart Association Detection Project in Industry Study]. Diabetes Care 1997;20:163-9
5. Balkau B, Shipley M, Jarrett PJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policeman Study. Diabetes Care 1998;21:360-7
6. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999;22:920-4
7. Stratton IM, Adler AI, Neil HA, et al., on behalf of the UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000;321:405-12
8. Khaw K-T, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of Cancer and Nutrition (EPIC-Norfolk). Br Med J 2001;322:15-8
9. Laakso M, Kuusisto J. Epidemiological evidence for the association of hyperglycaemia and atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Ann Med 1996;28:415-8
10. Nakagami T, for the DECODA Study Group. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 2004;47:385-94
11. Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Diabetes 1987;36:689-92
12. Jackson CA, Yudkin JS, Forrest RD. A comparison of the relationships of the glucose tolerance test and the glycated haemoglobin assay with diabetic vascular disease in the community. The Islington Diabetes Survey. Diabetes Res Clin Pract 1992;17:111-23
13. DECODE Study Group, on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397-405
14. Fuller JH, Shipley JJ, Rose G, Jarrett RJ, Keen H. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. Lancet 1980;1:1373-6
15. Jarrett RJ, McCartney P, Keen H. The Bedford Survey: ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics. Diabetologia 1982;22:79-84
16. Eschwege E, Richard JL, Thibult N, et al. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study, ten years later. Horm Metab Res Suppl 1985;15:41-6
17. de Vegt F, Dekker JM, Ruhè HG, Stehouwer CDA, Nijpels G, Heine RJ. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999;42:926-31
18. Reichard P, Berglund B, Britz A, Cars I, Nilsson BY, Rosenqvist U. Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. J Intern Med 1991;230:101-8
19. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 1993;329:977-86
20. Malmberg K, for the DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. Br Med J 1997;314:1512-5
21. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, for the STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-7
22. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
23. 1c. Diabetes Care 2003;26:881-5
24. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 1997;20:1822-6
25. 1c in the Diabetes Control and Complications Trial. Diabetes Care 2002;25:275-8
26. 1c. IOEZ Study Group. Diabetes Care 2000;23:1236-41
27. Dowse GK. Incidence of NIDDM and the natural history of IGT in Pacific and Indian Ocean populations. Diabetes Res Clin Pract 1996;34(Suppl):S45-S50
28. DECODA Study Group. Age- and sex-specific prevalence of diabetes and impaired glucose regulation in 11 Asian cohorts. Diabetes Care 2003;26:1770-80
29. Yano K, Kagan A, McGee D, Rhoads GG. Glucose tolerance and nine-year mortality in Japanese men in Hawaii. Am J Med 1982;72:71-80
30. Gavin 3rd JR. Pathophysiologic mechanisms of postprandial hyperglycemia. Am J Cardiol 2001;88:4H-8H
31. Dinneen SF. Mechanism of postprandial hyperglycaemia in diabetes mellitus. Eur J Gastroenterol Hepatol 1995;7:724-9
32. Del Prato S. Loss of early insulin secretion leads to postprandial hyperglycaemia. Diabetologia 2003;46(Suppl 1):M2-M8
33. Suzuki H, Fukushima M, Usami M, et al. Factors responsible for development from normal glucose tolerance to isolated postchallenge hyperglycemia. Diabetes Care 2003;26:1211-5
34. Fukushima M, Usami M, Ikeda M, et al. Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes. Metabolism 2004;53:831-5
35. Dickinson S, Colagiuiri S, Faramus E, Petocz P, Brand-Miller C. Postprandial hyperglycemia and insulin sensitivity differ among lean adults of different ethnicities. J Nutr 2002;132:2574-9
36. Uchino H, Niwa M, Shimizu T, Nishiyama K, Kawamori R. Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogue. Endocr J 2000;47:639-41
37. Saloranta C, Hershon K, Ball M, Dickinson S, Holmes D. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. J Clin Endocrinol Metab 2002;87:4171-6
38. Rosenstock J, Shen SG, Gatlin MR, Foley JE. Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes. Diabetes Care 2002;25:1529-33
39. Horton ES, Foley JE, Shen SG, Baron MA. Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naive patients with type 2 diabetes. Curr Med Res Opin 2004;20:883-9
40. Saloranta C, Guitard C, Pecher E, et al. Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population. Diabetes Care 2002;25:2141-6
41. Hanefeld M. Postprandial hyperglycaemia: noxious effects on the vessel wall. Int J Clin Pract Suppl 2002;129:45-50
42. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 2005;54:1-7
43. Lin Y, Berg AH, Iyengar P, et al. The hyperglycemia-induced inflammatory response in adipocytes: the role of reactive oxygen species. J Biol Chem 2005;280:4617-26
44. Risso A, Mercuri F, Quagliaro L, Damante G, Ceriello A. Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol Endocrinol Metab 2001;281:E924-E930
45. Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H, Dandona P. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J Clin Endocrinol Metab 2000;85:2970-3
46. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002;106:2067-72
47. Esposito K, Giugliano D, Nappo F, Marfella R, for the Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycaemia in type 2 diabetes mellitus. Circulation 2004;110:214-9
48. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998;97:2007-11
49. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101:1767-72
50. Bermudez EA, Rifai N, Buring J, Manson JE, Ridker PM. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol 2002;22:1668-73
51. Ceriello A, Quagliaro L, Piconi L, et al. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 2004;53:701-10
52. Ceriello A, Taboga C, Tonutti L. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 2002;106:1211-18
53. Shimabukuro M, Higa N, Takasu N, Tagawa T, Ueda S. A single dose of nateglinide improves post-challenge glucose metabolism and endothelial dysfunction in Type 2 diabetic patients. Diabetic Med 2004;21:983-6
54. Ceriello A, Quagliaro L, Catone B, et al. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care 2002;25:1439-43
55. Hanefeld M, Koehler C, Henkel E, Fuecker K, Schaper F, Temelkova-Kurktschiev T. Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: the RIAD Study. Diabetic Med 2000;17:835-40
56. 1c level. Diabetes Care 2000;23:1830-4
57. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study (UKPDS) VIII, study design, progress and performance. Diabetologia 1991;34:877-90
58. Califf R, Holman R, on behalf of the NAVIGATOR Trial Group. People at increased risk of cardiovascular disease screened for the NAVIGATOR Trial frequently have undiagnosed diabetes or impaired glucose tolerance [Abstract and poster 1169-51]. 52nd annual scientific session of the American College of Cardiology, Chicago, 30 March-2 April 2003
59. Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men [The Rancho Bernado Study]. Diabetes Care 1998;21:1236-9
60. Ceriello A. The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia 2003;46:M9-M16
61. Ebenbichler CF, Kirchmair R, Egger C, Patsch JR. Postprandial state and atherosclerosis. Curr Opin Lipidology 1995;6:286-90
62. Laakso M, Lehto S, Penttilä I, Pyörälä K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 1993;88:1421-30
63. Taskinsen M-R. LDL-cholesterol, HDL-cholesterol or triglycerides - which is the culprit? Diabetes Res Clin Pract 2003;61:S19-S26
64. Wilson PW, Kannel WB, Anderson KM. Lipids, glucose intolerance and vascular disease: the Framingham Study. Monogr Atheroscler 1985;13:1-11
65. Teno S, Uto Y, Nagashima H, et al. Association of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with type 2 diabetes. Diabetes Care 2000;23:1401-6
66. Mine T, Miura K, Kitahara Y, Okano A, Kawamori R. Nateglinide suppresses postprandial hypertriglyceridemia in Zucker fatty rats and Goto-Kakizaki rats: comparison with voglibose and glibenclamide. Biol Pharm Bull 2002;25:1412-6
67. Mori Y, Kuriyama G, Tajima N. Effects of nateglinide on the elevation of postprandial remnant-like particle triglyceride levels in Japanese patients with type 2 diabetes assessment by meal tolerance test. Endocrine 2004;25:203-6
68. Mori Y, Kitahara Y, Miura K, Mine T, Tajima N. Role of early insulin secretion in postglucose-loading hyperglycaemia and postfat-loading hyperlipidaemia: comparing nateglinide and glibenclamide for acute effects on insulin secretion in OLETF rats. Diabetes Obes Metab 2004;6:422-31
69. Vakkilainen J, Mero N, Schweizer A, Foley JE, Taskinen MR. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes. Diabetes Metab Res Rev 2002;18:484-90
70. Tentolouris N, Kolia M, Tselepis AD, et al. Lack of effect of acute repaglinide administration on postprandial lipaemia in patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2003;111:370-3
71. Johanson EH, Jansson PA, Gustafson B, et al. No acute effect of nateglinide on postprandial lipid and lipoprotein responses in subjects at risk for type 2 diabetes. Diabetes Metab Res Rev 2005 [Epub:Feb 22 2005]
72. European Diabetes Policy Group. A desktop guide to Type 2 diabetes mellitus. Diabetic Med 1999;16:716-30
73. Carroll MF, Gutierrez A, Castro M, Tsewang D, Schade DS. Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes. J Clin Endocrinol Metab 2003;88:5248-54
74. van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C. α-glucosidase inhibitors for patients with type 2 diabetes. Results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005;28:154-63
75. Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years [UK Prospective Diabetes Study 44]. Diabetes Care 1999;22:960-4
76. Fonseca V, Grunberger G, Gupta S, Shen S, Foley JE. Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control. Diabetes Care 2003;26:1685-90
77. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005;28:S4-S36
78. Kosaka K, Kikuchi M, Tarui S, et al. Phase-III study of a novel hypoglycaemic agent, AY1466, on NIDDM patients in Japan: α-glucosidase inhibitor, voglibose-controlled multicenter double blind study. Clin Pharmacol Ther 1997;7:699-727
79. Derosa G, Mugellini A, Ciccarelli L, Crescenzi G, Fogari R. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. Clin Ther 2003;25:472-84
80. Wolffenbuttel BH, Landgraf R. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. Diabetes Care 1999;22:463-7
81. Marbury T, Huang WC, Strange P, Lebovitz H. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res Clin Pract 1999;43:155-66
82. Siebenhofer A, Plank J, Berghold A, Narath M, Gfrerer R, Pieber TR. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2004;2:CD003287
83. Kokic S, Bukovic D, Radman M, et al. Lispro insulin and metformin versus other combination in the diabetes mellitus type 2 management after secondary oral antidiabetic drug failure. Coll Antropol 2003;27:181-7